Cofilin is a cAMP effector in mediating actin cytoskeleton reorganization and steroidogenesis in mouse and human adrenocortical tumor cells by E. Peverelli et al.
Q6
Q5
Q1
Q2
Q3
lable at ScienceDirect
Cancer Letters xxx (2017) 1e10
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
CAN13440_proof ■ 8 August 2017 ■ 1/10Contents lists avaiCancer Letters
journal homepage: www.elsevier .com/locate/canlet
56
57
58
59
60
61
62
63
64Original Article
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81Cofilin is a cAMP effector in mediating actin cytoskeleton
reorganization and steroidogenesis in mouse and human
adrenocortical tumor cells
E. Peverelli a, b, *, R. Catalano a, b, E. Giardino a, b, D. Treppiedi a, b, V. Morelli a, b,
C.L. Ronchi c, A. Vaczlavik d, e, N. Fusco f, g, S. Ferrero f, g, J. Bertherat d, e, F. Beuschlein h,
I. Chiodini a, b, M. Arosio a, b, A. Spada a, b, G. Mantovani a, b
a Endocrine Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italy
b Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
c Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Wuerzburg, Wuerzburg, Germany
d Institut Cochin, Inserm U1016, CNRS UMR8104, Descartes University, Paris, France
e Department of Endocrinology, Reference Center for Rare Adrenal Diseases, Ho^pital Cochin, Paris, France
f Division of Pathology, Fondazione IRCCS Ca’ Granda-Ospedale Maggiore Policlinico, Milan, Italy
g Department of Biomedical, Surgical and Dental Sciences, University of Milan Medical School, Milan, Italy
h Medizinische Klinik und Poliklinik IV, Endocrine Research Unit, Klinikum der Universit€at München, LMU, Munich, Germany82
83
84
85
86
87
88
89
90
91
92
93
94
95a r t i c l e i n f o
Article history:
Received 15 May 2017
Received in revised form
20 July 2017
Accepted 27 July 2017
Keywords:
Adrenocortical adenomas
Cofilin
Cytoskeleton
cAMP
CortisolAbbreviations: CPA, Cortisol-producing adrenoco
crine inactive adrenocortical adenomas; CS, Cushing's
* Corresponding author. Endocrinology and Diabeto
Ca’ Granda - Pad.Granelli, Via F. Sforza, 35, 20122, Mi
E-mail address: erika.peverelli@guest.unimi.it (E. P
http://dx.doi.org/10.1016/j.canlet.2017.07.025
0304-3835/© 2017 Elsevier B.V. All rights reserved.
96
97
98
99
100
101
102
Please cite this article in press as: E. Peverelli
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cAMP pathway plays a major role in the pathogenesis of cortisol-producing adrenocortical adenomas
(CPA). cAMP-induced steroidogenesis is preceded by actin cytoskeleton reorganization, a process regu-
lated by cofilin activity.
In this study we investigated cofilin role in mediating cAMP effects on cell morphology and ste-
roidogenesis in adrenocortical tumor cells.
We demonstrated that forskolin induced cell rounding and strongly reduced phosphorylated (P)-cofilin/
total cofilin ratio in Y1 (52 ± 16%, p < 0.001) and human CPA cells (53 ± 18%, p < 0.05). Cofilin silencing
significantly reduced both forskolin-induced morphological changes and progesterone production (1.3-
fold vs 1.8-fold in controls, p < 0.05), whereas transfection of wild-type or S3A (active), but not S3D
(inactive) cofilin, potentiated forskolin effects on cell rounding and increased3-fold progesterone synthesis
with respect to control (p < 0.05). Furthermore, cofilin dephosphorylation by a ROCK inhibitor potentiated
forskolin-induced cell rounding and steroidogenesis (2-fold increase vs forskolin alone).
Finally, we found a reduced P-cofilin/total cofilin ratio and increased cofilin expression in CPA vs
endocrine inactive adenomas by western blot and immunohistochemistry.
Overall, these results identified cofilin as a mediator of cAMP effects on both morphological changes
and steroidogenesis in mouse and human adrenocortical tumor cells.
© 2017 Elsevier B.V. All rights reserved.103
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Cortisol-producing adrenocortical adenomas (CPA) are the most
common cause of ACTH-independent Cushing's syndrome (CS).rtical adenomas; EIA, endo-
syndrome; LD, lipid droplets.
logy Unit, Fondazione IRCCS
lan, Italy.
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, et al., Cofilin is a cAMP effect
cells, Cancer Letters (2017), hGenetic alterations involving cAMP pathway are found in a
consistent proportion of CPA demonstrating a crucial role for cAMP
pathway in the pathogenesis of these tumors. The first genetic al-
terations described were inactivating mutations of phosphodies-
terase 11A (PDE11A) [1], but the more frequent ones are activating
mutations of catalytic subunit of protein kinase A (PKA) [2e4].
Although the central role of cAMP as second messenger medi-
ating the action of ACTH in adrenal cells is well recognized, the
molecular mechanisms that lead to cortisol secretion remain
largely unknown. cAMP/PKA activation effects include increased
activity of cholesterol ester hydrolase and steroidogenic acute
regulatory protein (StAR), and enhanced transcription of StAR and117
118
119
or inmediating actin cytoskeleton reorganization and steroidogenesis
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CAN13440_proof ■ 8 August 2017 ■ 2/10enzymes involved in steroidogenesis [5,6]. The rate-limiting step
and the key control point of adrenal steroidogenesis is the transport
of intracellular cholesterol, stored in cytoplasmic cholesterol ester
droplets, towards inner mitochondrial membrane, where ste-
roidogenesis begins.
Experimental evidence suggests that cAMP pathway regulates
this early step of cortisol biosynthesis through the modulation of
cell cytoskeleton. Indeed, it is well established that cAMP/PKA
pathway activation induces morphological changes accompanied
by cell rounding and disassembly of actin filaments and focal
adhesion in different steroidogenic cell types, including adrenal
[7e11], testicular [12,13] and ovarian granulosa cells [14e16].
Moreover, different inhibitors of actin polymerization affect
steroids production, and blocking cAMP-induced cell rounding also
inhibit steroidogenesis in mouse Y1 adrenocortical tumor cells
[7,10,17,18]. It has been proposed that cytoskeleton plays a promi-
nent role in the delivery of cholesterol from lipid droplets (LD) to
the mitochondrial membrane [19]. However, the biology that un-
derpins these mechanisms is a matter of controversy.
To date, the molecular players that mediate the cAMP-induced
cytoskeleton rearrangements, their relationship with cortisol syn-
thesis and their possible role in the pathogenesis of CPA have not
been investigated.
Actin cytoskeleton reorganization is regulated by cofilin, an
actin binding protein that severs actin filaments and initiates actin-
polymerization by increasing the number of actin-free barbed ends,
from which actin filaments (F-actin) polymerize, and by providing
actin monomers (G-actin) for polymerization. Cofilin activity is
negatively regulated by Rho GTPases-induced phoshorylation at
Ser3, a residue locatedwithin the cofilin actin binding domain, with
a consequent loss of its ability to bind actin [20], whereas different
phosphatases participate in cofilin reactivation. Our group and
others have recently provided evidence suggesting that alterations
in the cofilin pathway might be involved in tumor invasiveness
[21e24], in agreement with the key role of cofilin in promoting cell
migration. In addition, it has been shown that cofilin is required to
initiate progesterone secretion by preovulatory granulosa cells [16].
Interestingly, cofilin phosphorylation is reduced by cAMP in
ovarian granulosa cells [16], suggesting a link between cAMP
pathway and cofilin.
In this work we investigated a possible role of cofilin in medi-
ating the morphological changes and cortisol production induced
by cAMP in an adrenocortical tumor cell line, Y1, and in primary
cultured cells derived from human adrenocortical tumors. More-
over, we compared cofilin phosphorylation and expression levels in
tissue samples from human CPA and endocrine inactive adreno-
cortical adenomas (EIA).113
114
115
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Mouse and human adrenocortical cell cultures
Y1mouse adrenocortical tumor cell line (CCL-79) was purchased from American
Type Culture Collection (ATCC, Manassas, VA) and grown in F12-K Nut Mix medium
(Gibco, Invitrogen, Life Technologies Inc., Carlsband, CA) supplemented with 15% HS
(horse serum), 2,5% FBS (fetal bovine serum), 2 mM glutamine, 100U/ml penicillin,
and 100 mg/ml streptomycin (Gibco, Invitrogen, Life Technologies Inc., Carlsband,
CA) at 37 C in humidified atmosphere of 95% air-5% CO2.
After obtaining written informed consent, sixteen frozen tissue samples (CPA
n ¼ 8, EIA n ¼ 8) were subjected to protein extraction, and fresh tissues (CPA n ¼ 6)
were used to obtain primary cell cultures.
The diagnosis of CPA was made in the presence of signs and/or symptoms of
cortisol excess (i.e. striae rubrae, moon facies, buffalo hump and skin atrophy) and in
the presence (in at least 2 out of 3 different determination) of cortisol levels after
1 mg overnight dexamethasone suppression (1 mg-DST) >5.0 mg/dL (138 nmol/L) or
in the presence of 2 out of the following biochemical features: 1 mg-DST >3.0 mg/
dL (83 nmol/L), adrenocorticotroph hormone (ACTH) levels <10 pg/mL (2.2 pmol/L),
24-h urinary cortisol levels (UFC) > 70 mg/24-h (193 nmoL/24-h). The diagnosis of
EIA was made in the absence of signs and/or symptoms of cortisol excess and in thePlease cite this article in press as: E. Peverelli, et al., Cofilin is a cAMP effect
in mouse and human adrenocortical tumor cells, Cancer Letters (2017), hpresence of no more than 1 out of the following biochemical features: 1 mg-DST
>3.0 mg/dL (83 nmol/L), ACTH levels <10 pg/mL (2.2 pmol/L), UFC >70 mg/24-h (193
nmoL/24-h) [25]. In EIA patients, the surgical option was considered mandatory on
the basis of the increasing dimensions (>1 cm increase during 12 months of follow
up) or a size larger than 4 cm at the diagnosis. In all subjects, before the study in-
clusion, the determination of 24-h urinary fractionated metanephrines and aldo-
sterone/plasma renin activity ratio excluded the presence of pheochromocytoma
and aldosteronoma, respectively.
Fresh tissues were dissociated in Dulbecco's modified Eagle's medium (DMEM)
containing 2 mg/mL collagenase (Sigma Aldrich, St. Louis, MO) at 37 C for 2 h to
obtain primary cell cultures. The digested tissue was passed on a 100-mm filter
(nylon cell strainer, BD Transduction Laboratories, Lexington, UK) to remove undi-
gested material. The obtained cell suspension was centrifuged (1000 rpm, 10 min).
After this centrifugation step, cells were pelleted at the bottom of the tube, while
adipocytes were found on the surface as a ring due to their low density. At this step,
the adipocyte ring was transferred to a new tube, and discarded. Pelleted cells were
cultured in DMEM (Sigma Aldrich, St. Louis, MO) supplemented with 20% FBS, 2 mM
glutamine and 100U/ml penicillin, and 100 mg/ml streptomycin (Gibco, Invitrogen,
Life Technologies Inc., Carlsband, CA, USA).
Morphological analysis
Mouse Y1 cells and human adrenocortical tumor cells were treated with 10 mM
forskolin for 30 min and the degree of cell rounding was estimated by counting cells
displaying spherical shape in a given field, and expressing them as a percentage of
the total cells in view [10,26,27]. Each field contained aminimum of 30 cells, and the
observations were taken on five separate, random fields. The counting was per-
formed by two independent operators. Y1 cells, transfected with wild type, S3A, S3D
cofilin, or empty vector or silenced for cofilin were stimulated for 3 h with 10 mM
forskolin, since time course experiments showed no effects of cell rounding before,
and then analysed as described above.
For actin staining, Y1 cells and adrenocortical tumor cells were fixed with 4%
paraformaldehyde for 10 min and stained with Alexa Fluor 555 conjugated-
phalloidin (Invitrogen, Life Technologies Inc., Carlsbad, CA) for 20 min at room
temperature. After wash with PBS, cells were mounted on glass slides with ProLong
Diamond Antifade mounting medium (Life Technologies, Carlsbad, CA) and analysed
by both fluorescence microscopy (Axio Vert.A1, Zeiss) and TCS SP2 laser scanning
confocal microscope with a HeNe 543 nm laser and a 63  objective (HCX PL APO
63X/1.4e0.60 OIL) (Leica Microsystem, Deerfield, IL).
Western blot analysis
Western blot analysis was carried out on total proteins extracted from Y1 cells,
human primary cultured cells or adrenocortical tumor tissues. Cells were stimulated
with 10 mM forskolin and/or 2.5 mM Y27632 dihydrochloride ROCK inhibitor at
different time points (10, 30, 60, 120 min). Proteins were quantified by BCA, sepa-
rated on SDS/polyacylamide gel and transferred to a nitrocellulose filter. To detect
phosphorylated cofilin, an anti-phospho-cofilin primary antibody (1:1000, Cell
signalling, Danvers, MA) and an anti-rabbit peroxidase-linked secondary antibody
were used. The presence of total cofilin was analyzed by stripping and reprobing
with an anti-cofilin antibody (1:1000, Cell signalling, Danvers, MA). GAPDH was
used as housekeeping (1:4000, Ambion, Life Technologies Inc., Carlsband, CA).
Chemiluminescence was detected using the Chemidoc-IT Imaging System (UVP,
Upland, CA) and densitometrical analysis was performed with NIH ImageJ software.
Cofilin silencing and transfection
Small interfering RNAs (siRNAs, SMARTpool) for murine cofilin were synthe-
sized by Dharmacon (Chicago, IL). Y1 cells were transfected with Dharmafect re-
agent (Dharmacon, Chicago, IL), according to themanufacturer's instruction, for 72 h
prior to perform experimental treatments. In order to obtain the best efficiency of
cofilin silencing, four different Dharmafect reagents were tested. Preliminary ex-
periments to determine the optimal concentration of siRNAs and the kinetics of
silencing of cofilin were performed. A negative control siRNA, a non-targeting
sequence without significant homology to the sequence of mouse, human, or rat
transcripts, was used in each experiment.
Transient transfection of expression vectors containing GFP-tagged wild-type or
mutated cofilin (phosphodeficient S3A and phosphomimetic S3D) [21] was per-
formed in Y1 cells using Lipofectamine 3000 reagent (Invitrogen, Carlsband, CA)
according to the instruction of the manufacturer. Transfection efficiency was eval-
uated by fluorescence microscopy in each experiment. Only experiments with a
transfection efficiency >50% were accepted. Empty vector was used in each exper-
iment as control. Cells were transfected for 72 h prior to perform experimental
treatments.
Steroidogenesis assay
For progesterone determination, transfected and silenced Y1 adrenocortical
tumor cells were incubated for 24 h with forskolin 10 mM. To test the effects of
Y27632, cells were treated with 10 mM forskolin with or without 2.5 mM Y27632 foror inmediating actin cytoskeleton reorganization and steroidogenesis
ttp://dx.doi.org/10.1016/j.canlet.2017.07.025
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CAN13440_proof ■ 8 August 2017 ■ 3/103 h. Progesterone concentration in cell media was measured by Progesterone EIA Kit
(Cayman Chemical, Michigan USA) according to the manufacture's instruction.
For cortisol determination, human primary adrenocortical tumor cells were
treated with 10 mM forskolin with or without 2.5 mM Y27632 for 18 h and then
analysed by a specific immunoassay (Cortisol II, Cobas, Roche, Basel, Switzerland).
A pre-incubation with Y27632 for 30 min was performed prior to Y27632
incubation.
Oil Red O staining and quantification assay
Oil Red O stainingwas performed as previously described [28]. Briefly, cells were
washed with PBS, fixed by 10% formalin in PBS for 10 min at room temperature,
washed with PBS, and then stained with 60% filtered Oil Red O stock solution (0.35 g
Oil Red O (Sigma-Aldrich, Milan, Italy) in 100 ml isopropanol) for 20 min, washed
three times with water and then analyzed under a microscope (Axio Vert.A1, Zeiss).
Area of LD was measured by ISCapture software. At least 100 LD were analysed for
each condition.
Immunohistochemistry
Representative 4 mm-thick formalin-fixed paraffin embedded (FFPE) adreno-
cortical tumor sections (CPA n¼ 10, EIA n¼ 15) were stainedwith antibodies against
cofilin and phospho-cofilin (Ser3) (1:1000 and 1:50 respectively, both from Cell
Signaling, Danvers, MA) along with positive and negative controls. Human adre-
nocortical tumors primary cells were fixed by 10% formalin in PBS for 10min at room
temperature, washed with PBS, and then stained with S100 antibody (prediluted
from Ventana Medical Systems, Inc., Roche Group, AZ, USA).
Reactions were revealed using the ultraView Universal DAB (Ventana Medical
Systems Inc), as previously described [29]. Each stained slide was digitalized with
200X original magnification [30] and analyzed independently by two pathologists
(NF and SF) using a semi-quantitative system. Discordant results were reviewed over
a high-resolution monitor during a consensus meeting.
Statistical analysis
The results were expressed as themean ± standard deviation (SD). A paired two-
tailed Student's t-test was used to detect the significance between two series of data.
One-way ANOVA by Dunnett's test was used to determine the statistical differences
between treatments and the control group in multiple comparison.
CPA vs EIA densitometric data were analysed by the non-parametric Mann-
Whitney U test. In all analyses, a probability value p < 0.05 was accepted as statis-
tically significant. Biostatistics data were analysed using GraphPad Prism 5.0
software.
Results
Forskolin induced morphological changes and cofilin
dephosphorylation (activation) in Y1 cells and primary
adrenocortical tumor cells
Y1mouse adrenocortical tumor cells are flat, adherent cells with
polyhedral shape in basal culture condition. Forskolin treatment
induced cell rounding, with some rounded cells displaying long and
thin protrusions extending from the cell body (Fig. 1A). The per-
centage of rounded cells after 30 min of 10 mM forskolin was
74.2 ± 3.2% vs 11.8 ± 0.4% in control untreated cells (p < 0.001). In
basal condition, Y1 cell shape was maintained by a network of
stress fibers and focal adhesions, as shown by actin cytoskeleton
staining, whereas forskolin incubation induced the loss of actin
fibers and a redistribution of actin staining at cell periphery
(Fig. 1A).
Similar effects on cell morphology and actin cytoskeleton were
also observed in primary cortisol-secreting adrenocortical tumor
cells (Fig. 1B). Primary cell cultures were characterized by staining
with Oil Red O, that revealed the presence of intracellular LD with
the size and distribution typical of the steroidogenic cells (recently
reviewed in Ref. [31]) (Fig. 5C). The absence of a contamination of
adipose precursors was confirmed by the absence of staining for
marker of preadipocytes S100 [32] (data not shown) (see Fig. 6).
Time course experiments showed that 18 h incubation with
forskolin led to a significant increase of the percentage of rounded
cells (73.7 ± 11% vs 49.6 ± 17% in control untreated cells, p < 0.05). It
is worth noting that in basal condition the percentage of rounded
cells was higher compared to what observed in Y1 cells.Please cite this article in press as: E. Peverelli, et al., Cofilin is a cAMP effect
in mouse and human adrenocortical tumor cells, Cancer Letters (2017), hTo investigate the mechanism by which cAMP induces actin
cytoskeleton reorganization, we measured the effects of forskolin
on the phosphorylation of cofilin by western blot. Forskolin incu-
bation strongly reduced cofilin phosphorylation in Y1 cells, starting
from 10 min, with a maximum effect after 30 min (52 ± 16%
reduction of P-cofilin/total cofilin ratio, p < 0.001 vs basal), main-
tained at 60 min, and reverted at 120 min (Fig. 1C). A significant
reduction of P-cofilin/total cofilin ratio was also observed in pri-
mary cultured secreting adrenocortical tumor cells (53 ± 18% vs
basal, p < 0.05) (Fig. 1D).
Cofilin silencing in Y1 cells reduced forskolin effects on both cell
morphology and progesterone production
Since cofilin is a key protein in regulating the actin dynamics
and we found that it is positively regulated by cAMP, we hypoth-
esized that it might play a role in the cAMP-induced actin reorga-
nization in Y1 cells. To test this hypothesis, we knocked-down
cofilin expression in Y1 cells by genetic silencing.
Transient transfection of Y1 cells with siRNAs specific for cofilin
resulted in a reduction of 80% of cofilin expression with respect to
negative control siRNAs transfected cells (Fig. 2A). Cofilin silencing
did not alter basal cell morphology, but forskolin effects on cell
rounding were strongly impaired in cofilin silenced cells vs control
cells (37 ± 8% rounded cells in cofilin silenced cells vs 63 ± 7% in
control cells, p < 0.05) (Fig. 2B).
We then investigated a possible effect of cofilin silencing on Y1
steroidogenesis bymeasuring progesterone secretion, since Y1 cells
do not produce corticosterone [9,33]. Forskolin increased the pro-
gesterone amount 1.8-fold over basal in negative control cells cul-
ture media, and 1.3-fold in cells lacking cofilin (p < 0.05) (Fig. 2C),
suggesting that cofilin silencing significantly impaired the ability of
forskolin to stimulate progesterone production. A slight but not
statistically significant reduction of the basal progesterone pro-
duction was also observed in cofilin silenced cells (Fig. 2C).
Overexpression of wild type or phospho-deficient S3A mutant
cofilin, but not S3D cofilin, potentiated forskolin effects of on both
cell morphology and progesterone production in Y1 cells
We then tested the effects of cofilin overexpression and the role
of cofilin phosphorylation by transfecting Y1 cells with a phospho-
deficient mutant cofilin in which Ser3 is substituted with Ala (S3A
cofilin), a phospho-mimicking, inactive mutant of cofilin, namely
S3D, or wild type cofilin.
Forskolin-induced cell rounding was enhanced in wild type or
phospho-deficient S3A cofilin expressing cells (80 ± 6% and
85 ± 14% rounded cells, respectively) vs control cells transfected
with empty vector (69 ± 6% rounded cells, p < 0.05), but not in
phospho-mimicking S3D cofilin transfected cells (60 ± 3% rounded
cells) (Fig. 3A). No changes in Y1 cell morphology were observed in
the transfected cells under basal condition (Fig. 3A).
As expected, transfection of wild type or S3A cofilin, but not
inactive S3D cofilin, strongly increased the ability of forskolin to
induce steroidogenesis compared to control cells (2.7 and 2.8-fold
increase vs control cells, p < 0.05) (Fig. 3B).
Y27632 reduced cofilin phosphorylation and potentiated forskolin
effects on both cell morphology and steroidogenesis in Y1 cells and
primary cultured adrenocortical tumor cells
We tested whether alterations in cofilin phosphorylation status,
withoutmodification of cofilin expression levels, were able to affect
the cellular responses to cAMP pathway activation. Since to date no
pharmacological inhibitors of phosphatases that dephosphorylateor inmediating actin cytoskeleton reorganization and steroidogenesis
ttp://dx.doi.org/10.1016/j.canlet.2017.07.025
Fig. 1. Forskolin treatment induced morphological changes and cofilin dephosphorylation in Y1 cells and primary adrenocortical tumor cells. A) Y1 cells were treated for 30 min
with 10 mM forskolin and actin cytoskeleton was stained with phalloidin (red). Representative pictures show bright field (phase-contrast microscopy, 20X, upper panel), fluo-
rescence (20X, middle panel) and confocal (63X, lower panel) images. B) Primary cortisol-secreting adrenocortical tumor cells were treated for 18 h with 10 mM forskolin. Actin
cytoskeleton was stained with phalloidin (red). Representative pictures show bright field images (upper panel) and fluorescence images (lower panel). C&D) Forskolin reduced
cofilin phosphorylation in Y1 cells (C) and primary adrenocortical tumor cells (D). Cells were incubated for the indicated time with 10 mM forskolin. The graphs show the quan-
tification of P-cofilin/tot cofilin normalized vs respective basal (mean value ± SD from 4 independent experiments in Y1 cells and from 3 primary cultures of 3 different adre-
nocortical tumors, ** ¼ p < 0.01 vs basal). GAPDH was used as housekeeping. The figure shows representative immunoblots performed with phospho-cofilin, total cofilin and
GAPDH antibodies. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Fig. 2. Cofilin silencing in Y1 cells reduced forskolin effects on both cell morphology and progesterone synthesis. A) Y1 cells were transfected for 72 h with negative control siRNAs
(C) or siRNAs specific for mouse cofilin. The figure shows representative immunoblot performed with total cofilin and GAPDH antibodies. B) After 72 h of transfection with negative
control (C) or cofilin siRNAs, Y1 cells were treated for 3 h with 10 mM forskolin. Cell rounding was expressed as the percentage of round shaped cells (mean value ± SD from 3
independent experiments, * ¼ p < 0.05 vs negative control cells, x ¼ p < 0.05 vs bas, xxx ¼ p < 0.001 vs bas). C) Y1 cells were transfected for 72 h with negative control (C) or cofilin
siRNAs, treated with 10 mM forskolin for 3 h and progesterone secretionwas measured in cell media. The graph shows mean value normalized over the basal of negative control cells
±SD from 4 independent experiments. Each determination was done at least in triplicate. * ¼ p < 0.05 vs negative control cells, x ¼ p < 0.05 vs bas, xx ¼ p < 0.01 vs bas).
Fig. 3. Effects of transfection with wild type, phosphodeficient S3A or phosphomimicking S3D mutant cofilin on cell morphology and progesterone production in Y1 cells. A) After
72 h of transfection with the indicated constructs, Y1 cells were treated for 3 h with 10 mM forskolin. Cell rounding was expressed as the percentage of rounded cells (mean
value ± SD from 3 independent experiments, * ¼ p < 0.05 vs empty vector (EGFP) transfected cells, xxx ¼ p < 0.001 vs corresponding bas). B) Y1 cells were transfected for 72 h with
the indicated constructs, treated with 10 mM forskolin for 3 h and progesterone secretion in cell media was measured. The graph shows the mean value normalized over the
forskolin treated empty vector control cells ±SD from 3 independent experiments. Each determination was done at least in triplicate. * ¼ p < 0.05 vs forskolin treated control cells.
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CAN13440_proof ■ 8 August 2017 ■ 5/10cofilin are available, we evaluated the effects of blocking cofilin
phosphorylation. Y27632 is a cell-permeable, highly potent and
selective inhibitor of ROCK [21,34] a kinase that promotes cofilin
phosphorylation. Time course experiments in Y1 cells showed that
2.5 mM Y27632 induced a reduction of cofilin phosphorylation
comparable to that obtained with forskolin (59.45 ± 4% reduction
after 30 min incubation, p < 0.01) (Fig. 4A), a result replicated in
primary adrenocortical tumoral cells (Fig. 4B). Moreover, Y27632
exerted a synergistic effect together with forskolin in reducing
cofilin phosphorylation (83 ± 16% vs bas, p < 0.05, Fig. 4B).
Y27632 alone did not induce any detectable change in cell
morphology, but if used in combination with forskolin it acted
synergistically in promoting cell rounding both in Y1 cellsPlease cite this article in press as: E. Peverelli, et al., Cofilin is a cAMP effect
in mouse and human adrenocortical tumor cells, Cancer Letters (2017), h(90.9 ± 2.2% rounded cells vs 74.2 ± 3.2% with forskolin alone,
p < 0.01) (Fig. 4C) and in human adrenocortical tumor cells (90 ± 6%
rounded cells vs 73.7 ± 11% with forskolin alone, p < 0.05) (Fig. 4D).
Accordingly, with the synergistic effect observed on cell
morphology, incubation with Y27632 strongly potentiated for-
skolin effects on steroidogenesis. Indeed, in Y1 cells progesterone
secretion was increased by 4-fold over basal with forskolin alone
and 7.9-fold over basal in cells coincubated with forskolin and
Y27632 (Fig. 4E). In primary cultured cortisol-secreting adreno-
cortical tumor cells we found that forskolin-stimulated cortisol
production was strongly increased in the presence of Y27632 (3.3-
fold over basal in cells incubated with forskolinþY27632 vs 1.9-fold
in cells incubated with forskolin alone; Fig. 4F).or inmediating actin cytoskeleton reorganization and steroidogenesis
ttp://dx.doi.org/10.1016/j.canlet.2017.07.025
Fig. 4. A&B) ROCK inhibitor Y27632 reduced cofilin phosphorylation in Y1 cells (A) and primary cultured adrenocortical tumor cells (B). Cells were incubated for the indicated time
with 2.5 mM Y27632 with or without 10 mM forskolin. Primary adrenocortical tumor cells were incubated for 30min. The graphs show the quantification of P-cofilin/tot cofilin
normalized vs basal (mean value ± SD from 3 independent experiments in Y1 cells and from 3 adrenocortical tumors, ** ¼ p < 0.01 vs basal, *** ¼ p < 0.001 vs basal). The figures
shows representative immunoblots performed with phospho-cofilin and total cofilin antibodies. C&D) Y27632 potentiated forskolin effects on cell morphology of Y1 cells and
primary cultured adrenocortical tumor cells. Y1 cells were preincubated for 30 min with Y27632 as indicated and treated with 2.5 mM Y27632 and 10 mM forskolin for 30 min. Cell
rounding was expressed as the percentage of round shaped cells (mean value ± SD from 3 independent experiments, * ¼ p < 0.05 ** ¼ p < 0.01 vs control cells incubated with
forskolin but not Y27632, x ¼ p < 0.05 xxx ¼ p < 0.001 vs respective bas). E&F) Y27632 potentiated forskolin effects on steroidogenesis in Y1 cells and primary cultured adre-
nocortical tumor cells. E) Y1 cells were treated with Y27632 and forskolin as described in Materials and Methods for 3 h and progesterone amount in cell media was measured. The
graph shows the mean value normalized over basal ±SD from 5 independent experiments. Each determination was done at least in triplicate. * ¼ p < 0.05 vs forskolin alone treated
cells, x ¼ p < 0.05 vs bas, xx ¼ p < 0.01 vs bas. F) Primary cultured adrenocortical tumor cells were preincubated 30 min with 2.5 mM Y27632 and treated with 2.5 mM Y27632 and
10 mM forskolin for 18 h. Cortisol in cell media was measured by immunoassay. The graph shows the mean value normalized over basal ±SD from 3 independent experiments. Each
determination was done at least in triplicate. * ¼ p < 0.05 vs forskolin alone, x ¼ p < 0.05 vs respective bas, xx ¼ p < 0.01 vs respective bas.
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CAN13440_proof ■ 8 August 2017 ■ 6/10No differences in basal progesterone or cortisol secretion were
observed in Y27632 treated cells.
Y27632 potentiated forskolin effects on LD reduction in Y1 cells and
primary cultured adrenocortical tumor cells
To investigate a potential effect of cofilin in the delivery of
cholesterol from LD to the mitochondrial membrane, we measured
Oil Red O staining variations in Y1 cells and human primary cultures
of adrenocortical tumors after incubation with forskolin with or
without Y27632.We found that inboth cellmodels forskolin induced
a significant reduction of LD area (55% in Y1 cells and 64.6% in
primary cells) that is further reduced by cotreatment with Y27632
(65.1% in Y1 cells and 77.9% in primary cells) (Fig. 5AeC).Please cite this article in press as: E. Peverelli, et al., Cofilin is a cAMP effect
in mouse and human adrenocortical tumor cells, Cancer Letters (2017), hHuman CPA show increased cofilin expression and reduced P-cofilin/
total cofilin ratio in comparison to EIA
Finally, we tested a possible correlation with cofilin phosphor-
ylation status in human tissues of CPA or EIA. Western blot analysis
of the expression of P-cofilin and total cofilin in CPA (n¼ 8) and EIA
(n ¼ 8) showed that P-cofilin/total cofilin ratio was higher in EIA vs
CPA (mean P-cofilin/total cofilin ratio 2.44 and 0.76 respectively,
p < 0.05) (Fig. 5). Moreover, total cofilin/GAPDHwas lower in EIA vs
CPA (mean total cofilin/GAPDH ratio 0.54 and 1.20, respectively,
p < 0.01).
In agreement, immunohistochemistry revealed that CPA express
higher levels of cofilin than EIA (mean percentage of positive cells
67.8 ± 16.7% and 40.5 ± 30.7%, respectively, p < 0.05, Fig. 5B),130
or inmediating actin cytoskeleton reorganization and steroidogenesis
ttp://dx.doi.org/10.1016/j.canlet.2017.07.025
Fig. 5. Effects of forskolin and Y27632 on LD size. The graphs show LD area (mean value ± SD) in Y1 cells (A) and human primary adrenocortical cells (B). Cells were incubated with
10 mM forskolin with or without 2.5 mM Y27632 for 18 h and stained with Oil Red O. Area of LD was measured by ISCapture software. At least 100 LD were analysed for each
condition. *** ¼ p < 0.001 vs basal, xxx ¼ p < 0.001 vs forskolin alone. C) Representative pictures of human primary adrenocortical tumor cells treated as indicated for 18 h and
stained with Oil Red O. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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CAN13440_proof ■ 8 August 2017 ■ 7/10whereas a low percentage of P-cofilin positive cells was found in
both groups.
Overall, the increased cofilin expression and reduced cofilin
phosphorylation observed in CPA suggest that these tumors have
an increased activity of cofilin in respect to EIA.
Discussion
Despite the recognized leading role of the cAMP pathway in CPA
pathogenesis, the molecular mechanisms that lead to cortisol
secretion are poorly understood. The hypothesis of an active
contribution of cell cytoskeleton in the early steps of steroidogen-
esis has been strengthened by the widely recognized morpholog-
ical changes induced by cAMP, the most evident of which is cell
rounding that precedes steroidogenesis in different steroidogenic
cell types, although a clear causal correlation between these events
has yet to be proven.Please cite this article in press as: E. Peverelli, et al., Cofilin is a cAMP effect
in mouse and human adrenocortical tumor cells, Cancer Letters (2017), hTo the best of our knowledge, this is the first work that pro-
vides strong evidences to suggest that cofilin is a protein that
mediate cAMP effects on both actin cytoskeleton reorganization
and steroidogenesis in mouse and human adrenocortical tumor
cells.
In agreement with literature data, forskolin treatment of Y1 cells
induced the characteristic cell rounding, accompanied by actin
cytoskeleton rearrangements. We first replicated this action on
human primary cultured cells derived from adrenocortical lesions.
This morphological effect was associated with a transient reduction
of cofilin phosphorylation in both cell models. A cofilin phosphor-
ylation inhibitionmediated by cAMP/PKA activationwas previously
described in preovulatory granulosa cells [16], whereas a cAMP-
induced increase of cofilin phosphorylation was observed in other
cell types (mouse sperm and mouse embryonic fibroblasts) [35,36],
suggesting that the inhibitory pathway may be peculiar of ste-
roidogenic cell type.or inmediating actin cytoskeleton reorganization and steroidogenesis
ttp://dx.doi.org/10.1016/j.canlet.2017.07.025
Fig. 6. Human CPA showed increased cofilin expression and reduced P-cofilin/total cofilin ratio with respect to EIA. A) Representative immunoblot performed with phospho-cofilin,
total cofilin and GAPDH antibodies in tumor tissues (4 CPA and 5 EIA). The graph show the quantification of P-cofilin/tot cofilin and total cofilin/GAPDH in 8 CPA and 8 EIA (mean
value ± SD, * ¼ p < 0.05). B) Immunohistochemistry representative pictures showing P-cofilin and total cofilin staining in one CPA and one EIA tissue (20X magnification). The graph
shows percentage of P-cofilin and cofilin positive cells (mean ± SD, 10 CPA and 15 EIA, *p < 0.05).
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CAN13440_proof ■ 8 August 2017 ■ 8/10To test a possible causal role of cofilin dephosphorylation in
mediating forskolin effects we used three different approaches,
with consistent results: 1) genetic silencing of cofilin; 2) transient
transfection of wild type or mutated S3A and S3D cofilin; 3)
pharmacological inhibition of cofilin phosphorylation.
The morphological effects of cAMP, evaluated as percentage of
rounded cells, were impaired in cofilin silenced cells and increased
in wild type or phospho-deficient cofilin expressing cells or in cells
treated with Y27632, that potentiates forskolin effects by reducing
cofilin phosphorylation.
The same results observed on cell rounding after cofilin ma-
nipulations were reproduced on steroid synthesis, suggesting the
involvement of a common intracellular molecular mechanism.
It should be noted that cofilin silencing efficiency reached about
80%, with the remaining 20% of endogenous cofilin that might
explain the only partial suppression of forskolin induced cell
rounding and progesterone production.
The actions of cofilin on actin cytoskeleton reorganization
depend on its ability to bind actin, which in turn is regulated by
cofilin phosphorylation at Ser3 induced by Rho/ROCK pathway. In
agreement with these notions, we demonstrated that the over-
expression of wild-type or S3A cofilin by transient transfection in
Y1 cells potentiated forskolin effects, due to an increased cofilin
activity. On the contrary, the overexpression of S3D cofilin did notPlease cite this article in press as: E. Peverelli, et al., Cofilin is a cAMP effect
in mouse and human adrenocortical tumor cells, Cancer Letters (2017), hexert any effect on forskolin actions, probably because it does not
function as a dominant negative mutant, being not competitive
with endogenous dephosphorylated cofilin for the binding of actin,
as previously observed [21].
Accordingly, we found that altering only cofilin phosphorylation
status without affecting the expression level of total cofilin, by
using a specific inhibitor of ROCK [21,34], potentiated the cellular
responses to the cAMP pathway activation. It would be of great
interest to test a possible impairment of cAMP actions after stim-
ulation with pharmacological inhibitors of phosphatases that de-
phosphorylate cofilin, but unfortunately these compounds are not
available to date. Y27632 acted synergistically with forskolin in
promoting cell rounding and steroidogenesis in both Y1 cells and in
human adrenocortical tumor cells.
Since none of the cofilin manipulations itself induced any effect
on basal cell morphology nor on basal steroidogenesis without
forskolin co-incubation, we can hypothesize that cofilin activity is
necessary tomediate cAMP effects but is not sufficient to reproduce
cAMP actions, that involve a complex cascade of activation of
different molecular components.
Although we could test only few primary cultures of human
adrenocortical tumors, and silencing or transfection experiments
could not be performed due to technical limitation regarding the
number of viable cells that can be obtained from each tumor, thisor inmediating actin cytoskeleton reorganization and steroidogenesis
ttp://dx.doi.org/10.1016/j.canlet.2017.07.025
Q4
E. Peverelli et al. / Cancer Letters xxx (2017) 1e10 9
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
CAN13440_proof ■ 8 August 2017 ■ 9/10work clearly demonstrated that the data obtained in Y1 cell model
are well replicated in human cultures.
To investigate how the cAMP-induced cofilin activation in-
creases steroidogenesis we tested the effects of cAMP increase and
cofilin activation on intracellular cholesterol accumulation in LD.
Interestingly, Oil Red O staining for intracellular lipid accumulation
was decreased after foskolin treatment, with a synergistic effects of
Y27632, suggesting an increased mobilization of cholesterol from
its storage in LD. Our data are in agreement with previous obser-
vation supporting a role for cytoskeleton in the delivery of
cholesterol from LD to the mitochondrial membrane. Indeed,
mitochondrial cholesterol content in adrenal tissues was lower in
the cytoskeleton protein vimentin null mice, characterized by a
defective steroidogenesis [37]. Moreover, phosphotyrosin phos-
phatase inhibitors, that block steroidogenesis in Y1 cells, have no
effect on steroid production from 22(R)-hydroxycholesterol, the
hydrosoluble cholesterol derivative that can freely cross the mito-
chondrial membranes [10]. A possible role for actin in regulating
lipid transport is also supported by the beta-actin association with
intracellular LD observed in rat adrenocortical cells [38].
The strong impact of cofilin activity on cortisol production was
supported by the analysis of cofilin expression and phosphorylation
status in CPA vs EIA. Western blot analysis demonstrated a signifi-
cant increase of total cofilin expression levels and a reduction of P-
cofilin/total cofilin ratio in CPA vs EIA, accordingly with the pro-
posed role of active, dephosphorylated cofilin as mediator of cAMP-
induced cortisol overproduction in adrenocortical adenomas. It
should be noted that the reduction of cofilin phosphorylation may
be due to the observed increase of the expression of total cofilin in
CPA vs EIA without a proportional increase of expression/activity of
the kinases that phosphorylate cofilin. Immunohistochemistry
analysis confirmed a significant increase in cofilin expression in
CPA vs , further supporting the hypothesis of high levels of cofilin
activity in CPA with respect to EIA.
The reduced phosphorylation of cofilin in CPA is consistent with
the constitutive activation of cAMP pathway in this type of tumor,
mainly due to genetic alterations involving the catalytic subunit of
PKA. On the contrary, EIA have been associated with genetic al-
terations involving Wnt/b-catenin signaling pathway [39]. Since
cofilin promoter is predicted to contain a cAMP-response element
(CRE) [40], also the high levels of cofilin expression might be
explained by the constitutive cAMP pathway activation in CPA, but
further studies are required to test this hypothesis.
Since the available inhibitors of adrenal steroidogenesis that
may control hypercortisolism in CS have variable efficacy and sig-
nificant side effects, to date the management of CS remains chal-
lenging [41]. Dissecting the molecular mechanism involved in
cortisol synthesis might hopefully open the way to the discovery of
new molecular targets.
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